KALV

11.25

3.27% -0.38

Dopo l'orario di chiusura: 11.36 0.11 +0.98%

Kalvista Pharmaceuticals Inc (KALV)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$11.63

Aprire:

$11.45

Volume 24 ore:

621.25K

Relative Volume:

1.81

Capitalizzazione di mercato:

$453.33M

Reddito:

Utile/perdita netta:

$-108.30M

Rapporto P/E:

-3.5601

EPS:

-3.16

Flusso di cassa netto:

$-97.15M

1 W Prestazione:

-4.58%

1M Prestazione:

-0.97%

6M Prestazione:

-7.25%

1 anno Prestazione:

+29.76%

Intervallo 1D:

$10.78

$11.68

Intervallo di 1 settimana:

$10.01

$12.85

Portata 52W:

$7.21

$16.88

Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile

Nome

Kalvista Pharmaceuticals Inc

Settore

Healthcare (1182)

Industria

Biotechnology (671)

Telefono

(857) 999-0075

Indirizzo

55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA

Dipendente

Cinguettio

@kalvista

Prossima data di guadagno

2024-09-05

Ultimi documenti SEC

KALV's Discussions on Twitter

Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2020-06-15	Iniziato	H.C. Wainwright	Buy
2019-07-29	Iniziato	SVB Leerink	Outperform
2019-03-20	Iniziato	Needham	Buy
2018-10-30	Iniziato	Jefferies	Buy
2018-09-21	Iniziato	Cantor Fitzgerald	Overweight
2017-08-31	Iniziato	BTIG Research	Buy

Mostra tutto

Kalvista Pharmaceuticals Inc Borsa (KALV) Ultime notizie

07:39 AM

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - BioSpace

07:39 AM

07:29 AM

KalVista Secures $184M Financing for Sebetralstat Launch - Yahoo Finance

07:29 AM

02:29 AM

Vanguard Group Inc's Strategic Acquisition in KalVista Pharmaceu - GuruFocus.com

02:29 AM

02:11 AM

KalVista sets pricing for $60 million stock offering By Investing.com - Investing.com Canada

02:11 AM

Nov 04, 2024

KalVista Pharmaceuticals Shares Rise 11% on Royalty Financing Deal, Stock Offering - Marketscreener.com

Nov 04, 2024

DRI Healthcare Trust Announces Acquisition of a Synthetic Royalty Interest in the Worldwide Sales of Sebetralstat for the Treatment of Hereditary Angioedema Plus an Equity Investment in KalVista Pharmaceuticals - Barchart

Nov 04, 2024

Canadian Dollar/Australian Dollar (CADAUD) QuotePress Release - The Globe and Mail

Nov 04, 2024

KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million - StockTitan

Nov 04, 2024

KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust - StockTitan

Nov 04, 2024

Nov 03, 2024

KalVista Pharmaceuticals, Inc. announced that it expects to receive $5 million in funding from DRI Capital Inc. - Marketscreener.com

Nov 03, 2024

Emerald Advisers LLC Purchases 192,091 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - MarketBeat

Nov 03, 2024

Nov 02, 2024

(KALV) Long Term Investment Analysis - Stock Traders Daily

Nov 02, 2024

Oct 30, 2024

Hereditary Angioedema Market Forecasted to Surge in Coming - openPR

Oct 30, 2024

Oct 28, 2024

sebetralstat shows promise in phase 3 HAE trial By Investing.com - Investing.com South Africa

Oct 28, 2024

sebetralstat shows promise in phase 3 HAE trial - Investing.com India

Oct 28, 2024

KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology - The Bakersfield Californian

Oct 28, 2024

Oct 24, 2024

Hereditary Angioedema Market Size is Set for Rapid Growth as - openPR

Oct 24, 2024

Oct 22, 2024

(KALV) Trading Report - Stock Traders Daily

Oct 22, 2024

Oct 20, 2024

The Manufacturers Life Insurance Company Buys 3,314 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Oct 20, 2024

Oct 18, 2024

KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) - Milton Daily Standard

Oct 18, 2024

Oct 16, 2024

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Update - MarketBeat

Oct 16, 2024

Oct 14, 2024

Plasma Protease C1 Inhibitor Market Size, Development Growth, - openPR

Oct 14, 2024

Oct 12, 2024

(KALV) Technical Data - Stock Traders Daily

Oct 12, 2024

Oct 10, 2024

Marshall Wace LLP Has $576,000 Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - MarketBeat

Oct 10, 2024

Oct 09, 2024

Sweden Hereditary Angioedema Therapeutics Market Size & Outlook, 2030 - Grand View Research

Oct 09, 2024

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stake Decreased by Dimensional Fund Advisors LP - MarketBeat

Oct 09, 2024

Oct 08, 2024

Kalvista shares hold Buy rating, price target on HAE study By Investing.com - Investing.com South Africa

Oct 08, 2024

Kalvista shares hold Buy rating, price target on HAE study - Investing.com

Oct 08, 2024

Oct 07, 2024

KalVista Pharmaceuticals (NASDAQ:KALV) Earns Buy Rating from HC Wainwright - MarketBeat

Oct 07, 2024

Kalvista asks 4 countries to OK sebetralstat as treatment for HAE - Angioedema News Today

Oct 07, 2024

Oct 05, 2024

KalVista Pharmaceuticals announces board election results - Investing.com India

Oct 05, 2024

Oct 04, 2024

KalVista Pharmaceuticals announces board election results By Investing.com - Investing.com Australia

Oct 04, 2024

Sebetralstat shows promise for anxiety in HAE attacks By Investing.com - Investing.com South Africa

Oct 04, 2024

Sebetralstat shows promise for anxiety in HAE attacks - Investing.com

Oct 04, 2024

KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum - BioSpace

Oct 04, 2024

KALVKalVista Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan

Oct 04, 2024

Oct 03, 2024